Everest Medicines Announces New Strategic Plans, Reinforcing Transformation into a Fully Integrated Biopharmaceutical Company
Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, has announced its strategic plans for the next two years and beyond as the Company progresses to becoming a fully-integrated biopharmaceutical company with expertise and capabilities across the full biotechnology value chain, including proven self-discovery and in-licensing, clinical development, and established manufacturing and commercialization. The Company’s renal disease and mRNA platform portfolios, both of which comprise multiple promising early- and late-stage therapeutic candidates, will be Everest’s core areas of focus.
“Everest had impressive growth over the past five years, evolving from its successful in-licensing model to developing strong capabilities in both self-discovery and business development, both of which we will continue to leverage as we transition into a fully integrated biopharma company and establish ourselves as an Asia-based industry leader with a global footprint,” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “In this next phase of corporate growth, we are focused on building commercialization capacities that will enable the successful launch of multiple late-stage assets over the next five years spearheaded by Nefecon.”
The potential approval and launch of Nefecon, the Company’s lead renal portfolio product candidate, is expected in China in the second half of 2023. China has the world’s highest prevalence of primary glomerular disease and IgA nephropathy is the most common glomerular disease with around 5 million patients in the country.
In parallel, the Company aims to initiate clinical trials and file an Emergency Use Authorization application in 2023 in China for its lead mRNA candidate, EVER-COVID19-M1, a bivalent COVID-19 booster. In just under 16 months since its partnership with Providence Therapeutics Holdings Inc., Everest has completed industrial-scale technology transfer, advanced its clinically-validated mRNA platform, and successfully carried out trial production runs at its commercial-scale manufacturing facility in Jiashan, China. In addition to its COVID-19 program, Everest will continue to harness the full potential of its mRNA technology platform to drive development of preventive and therapeutic vaccines against various infectious diseases and cancers.
In addition to the Everest Medicines focus on renal diseases and mRNA platform, it also plans to pursue several product candidates in the pipeline with best-in-class potential, including Xerava which is also expected to receive NDA approval in 2023, and etrasimod for the treatment of ulcerative colitis.
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more
- Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) Read more
- ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment Read more